Morten Aagaard Petersen

Morten Aagaard Petersen

Auto-generated profile, based on publicly available information

Morten Aagaard Petersen

Department of Geriatrics and Palliative Medicine GP, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in European Journal of Cancer
Verified
Journal Article
Closed access
MGMogens Groenvold
Mogens Groenvold
MPMorten Aa. Petersen
Morten Aa. Petersen
NANeil K. Aaronson
Neil K. Aaronson
JAJuan I. Arraras
Juan I. Arraras
JBJane M. Blazeby
Jane M. Blazeby
JBJakob B. Bjorner
Jakob B. Bjorner

1 January 2016 in Journal of Clinical Epidemiology
Verified
Journal Article
Open access
JGJohannes M. Giesinger
Johannes M. Giesinger
JKJacobien M. Kieffer
Jacobien M. Kieffer
PFPeter M. Fayers
Peter M. Fayers
MGMogens Groenvold
Mogens Groenvold
MPMorten Aa. Petersen
Morten Aa. Petersen
NAN.K. Aaronson
N.K. Aaronson
To further evaluate the higher order measurement structure of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30), with the aim of generating a summary score. Using pretreatment QLQ-C30 data (N = 3,282), we conducted confirmatory factor analyses to test seven previously evaluated higher order models. We compared the summary score(s) derived from the best performing higher order model with the original QLQ-C30 scale scores, using tumor stage, performance status, and change over time (N = 244) as grouping variables. Although all models showed acceptable fit, we continued in the interest of parsimony with known-groups validity and responsiveness analyses using a summary score derived from the single higher order factor model. The validity and responsiveness of this QLQ-C30 summary score was equal to, and in many cases superior to the original, underlying QLQ-C30 scale scores. Our results provide empirical support for a measurement model for the QLQ-C30 yielding a single summary score. The availability of this summary score can avoid problems with potential type I errors that arise because of multiple testing when making comparisons based on the 15 outcomes generated by this questionnaire and may reduce sample size requirements for health-related quality of life studies using the QLQ-C30 questionnaire when an overall summary score is a relevant primary outcome.

3 January 2007 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MGMogens Groenvold
Mogens Groenvold
MPMorten Aagaard Petersen
Morten Aagaard Petersen
EIEllen Idler
Ellen Idler
JBJakob Bue Bjorner
Jakob Bue Bjorner
PFPeter M. Fayers
Peter M. Fayers
HMHenning T. Mouridsen
Henning T. Mouridsen

2 July 2009 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
AJAnna T. Johnsen
Anna T. Johnsen
DTDorte Tholstrup
Dorte Tholstrup
MPMorten Aa. Petersen
Morten Aa. Petersen
LPLise Pedersen
Lise Pedersen
MGMogens Groenvold
Mogens Groenvold
Objectives:  Knowledge of health related quality of life of haematological patients is limited. This study aimed at investigating the prevalence and predictors of symptoms and problems in a representative sample of haematological patients in Denmark.Methods:  A random sample of patients with leukaemia, multiple myeloma and advanced lymphoma (n = 732) received the European Organisation for Research and Treatment of Cancer quality‐of‐life questionnaire (EORTC QLQ‐C30). Mean scores were calculated. In addition, scores were dichotomised using two thresholds: patients reporting at least ‘a little’ of each EORTC QLQ‐C30 symptom/problem were classified as having a ‘symptom/problem’, and patients reporting at least ‘quite a bit’ were classified as having a ‘severe symptom/problem’. Multiple logistic regression was used to identify predictors.Results:  In total, 470 (64%) patients participated. The most frequent symptoms/problems were fatigue (55%; severe 20%), reduced role function (49%; severe 23%), insomnia (46%; severe 15%), and pain (37%; severe 15%). Older patients and patients in active antineoplastic treatment had more symptoms and problems. There was only little evidence of social inequalities.Conclusion:  This is probably the first nationally representative study of symptoms and problems in haematological patients. These patients have symptoms/problems that deserve attention. Health related quality of life is an important issue in haematological malignancies.

1 March 2009 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
NSNeil W Scott
Neil W Scott
PFPeter M Fayers
Peter M Fayers
NANeil K Aaronson
Neil K Aaronson
ABAndrew Bottomley
Andrew Bottomley
AGAlexander De Graeff
Alexander De Graeff
QGQuality of Life Cross-Cultural Meta-Analysis Group
Quality of Life Cross-Cultural Meta-Analysis Group

1 June 2003 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
MPMorten Aa. Petersen
Morten Aa. Petersen
MGMogens Groenvold
Mogens Groenvold
JBJakob B. Bjorner
Jakob B. Bjorner
NANeil Aaronson
Neil Aaronson
TCThierry Conroy
Thierry Conroy
MSMarianne Sullivan
Marianne Sullivan